alexa Visual Binding: A Radically New Concept To Support The Medicinal Chemist?s Quest For Innovative NMEs
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Carsten Detering
ScientificTracks Abstracts: Med Chem
DOI: 10.4172/2161-0444.S1.011
The introduced next generation of binding affinity assessment tool Hyde, has been incorporated into a new software, SeeSAR, which helps the medicinal chemist assess, modify and prioritize compounds within the context of the protein. Hyde has been completely revamped and shows another huge step forward to accurate compound scoring. After having optimized the protein-ligand complex, Hyde accounts for the hydrogen bond and desolvation energy of a ligand binding to a protein, effectively ruling out false positives by incorporating penalties for unmet interactions. Those penalties are visually communicated, giving intuitive clues where to improve the molecule with respect to binding affinity. An interactive editor helps making the necessary modifications, and the scientist gets immediate feedback whether those changes are leading into the right direction, i.e. if the binding affinity is getting better or not. The talk will highlight the science behind Hyde as well as case studies which demonstrate Hyde?s effectiveness.
Carsten Detering obtained his PhD in Physical Chemistry from the Freie Universitaet Berlin in Germany in 2001. He did his Post Doc at the University of Washington in Seattle where he worked on the application of docking software for nucleic acid drug targets and rational design of new inhibitors for a malaria project. In 2005 he came to BioSolveIT in Germany as an Application Scientist first, later filling the position of Senior Key Account Manager and Executive VP of Sales, North America, before moving back to Seattle as CEO of BioSolveIT Inc., the north American subsidiary of BioSolveIT.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version